FDA OK makes As­traZeneca the leader in one new seg­ment of the all-im­por­tant lung can­cer mar­ket

As­traZeneca $AZN has found a way to jump out in front of a pack of heavy­weight PD-1/L1 ri­vals duk­ing it out for a big piece of the block­buster lung can­cer mar­ket.

The day af­ter Pfiz­er and Mer­ck KGaA were forced to throw in the tow­el on a piv­otal sec­ond-line lung can­cer study for Baven­cio, the FDA hand­ed the UK phar­ma gi­ant an ap­proval to mar­ket Imfinzi to pa­tients whose stage III non-small cell lung can­cer hasn’t pro­gressed af­ter chemora­di­a­tion and whose tu­mors can’t be sur­gi­cal­ly re­moved.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER